12.02.25 -- How Early Manufacturing Decisions Shape Long-Term Success

Aseptic drug manufacturing is going small. Discover how advanced robotic and automated systems with smaller footprints are changing the landscape and boosting accessibility.

Despite the rise of single-use bags, bottles continue to play a significant role in bioprocessing for the production of robust products. New closed-system technologies and sustainable materials could boost their popularity.

Western blotting identifies specific proteins in complex samples, using gel electrophoresis and antibody probing. Find out how it reveals protein presence, abundance, and size.

Small-scale perfusion-mimic models can effectively predict media performance in continuous bioreactors to help optimize cell density, productivity, and scalability for CHO cell lines.

Watch as speakers share a variety of challenges encountered when closing and automating ancillary processes, and how closed automated platforms improved scalability and reproducibility.

Manual processes are yielding to automated, GMP-compliant closed systems in CGT manufacturing. This shift is crucial for meeting Annex 1 contamination standards and creating scalable, reliable commercial production.

A study demonstrates how a low-shear, closed-system centrifuge achieved over 90% MSC recovery and minimized viability loss, supporting scalable cell therapy manufacturing.

Expand your knowledge on the latest innovation in the sterile connector space including the new 1.5” flow path connector, disconnection solution, and more.

Review a novel adenovirus production process that offers scalable, single-use equipment-compatible solutions, reducing production time and cross-contamination risks.

Maintenance of CCI at ultra-low temperature is a necessity for a gene therapy vial containment system. Systems comprising cyclic olefin polymer vials and elastomer stoppers with a barrier film were evaluated over time.

Achieve scalable, non-viral CRISPR delivery for T cells. The next-generation electroporation platform provides robust, efficient gene editing from small to large-scale volumes.

In cell culture, the leakage of toxic or inhibitory chemicals from single-use bioreactors has become a growing concern. Explore recommendations for leachable studies.

By increasing recombinant AAV titers, this AAV enhancer can help reduce upstream manufacturing costs and lower the cost per therapeutic dose.

Addressing critical hurdles in CAR-T cell production, this research demonstrates methods to enhance efficiency and reduce expenses for broader patient benefit.